Ceftobiprole medocaril
| Recommendation | No dose adjustment appears necessary |
|---|---|
| Comments | Post hoc analysis of three Phase 3 trials suggests safety and efficacy maintained without dose adjustment. Possible signal of reduced efficacy in severe obesity, requires further investigation (J Antimicrob Chemother 2025;80:1526). |